Biomea Fusion Inc. (NASDAQ: BMEA) announced 52-week results from its Phase 2 COVALENT-112 trial testing icovamenib in patients with type ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE